Nivolumab and Ipilimumab for Metastatic Castration-Resistant Prostate Cancer With an Immunogenic Signature: The Multicenter, Two-Cohort, Phase II NEPTUNES Study.

Journal:

Journal of Clinical Oncology

Published:

2025-07-29

DOI:

10.1200/jco-24-02637

Affiliations:

13

Authors:

28

Go to article

Institutions	Authors	Share
UCL, United Kingdom (UK)	10.500000 10.500000	0.38
University College London Hospitals NHS Foundation Trust (UCLH), United Kingdom (UK)	4.000000	0.14
Cancer Research UK and UCL Cancer Trials Centre (UCL CTC), United Kingdom (UK)	3.000000	0.11
UW Medicine, United States of America (USA)	2.000000	0.07
Derriford Hospital, United Kingdom (UK)	1.000000	0.04
Southampton Experimental Cancer Medicine Centre (Southampton ECMC), United Kingdom (UK)	1.000000	0.04
Leeds Teaching Hospitals NHS Trust (LTHT), United Kingdom (UK)	1.000000	0.04
Beatson West of Scotland Cancer Centre (BWoSCC), United Kingdom (UK)	1.000000	0.04
Guy's and St Thomas' NHS Foundation Trust, United Kingdom (UK)	1.000000	0.04
Oxford University Hospitals NHS Trust (OUH), United Kingdom (UK)	1.000000	0.04
University Hospitals Birmingham NHS Foundation Trust (UHB), United Kingdom (UK)	1.000000	0.04
Velindre Cancer Centre, Velindre NHS Trust, United Kingdom (UK)	1.000000	0.04
National Cancer Centre Singapore (NCCS), Singapore	0.500000	0.02

Interested in Oncology and Carcinogenesis?